Immunosuppressive treatment in primary focal segmental glomerulosclerosis

Abstract

Background: The therapeutic effects of immunosuppressive agents such as cyclosporin A, mycophenolate mofetil, rituximab and sirolimus on primary focal segmental glomerulosclerosis (FSGS) remain controversial. The present study was intended to review and analyze the treatment results of immunosuppressive agents for primary FSGS in child and adult patients.

Methods: Complete remission rates and partial remission rates were extracted from published articles and analyzed using statistical tests.

Results: Cyclosporin A was effective in the treatment of child and adult patients with idiopathic FSGS. Rituximab therapy displayed a higher complete remission and partial remission rate in children than in adult FSGS patients.

Conclusions: Multiple-center large-scale rigorous trials should be considered to evaluate the risk-benefit ratio of immunosuppressive treatment in patients with primary FSGS.